BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11008119)

  • 1. Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase.
    Mao C; Sudbeck EA; Venkatachalam TK; Uckun FM
    Biochem Pharmacol; 2000 Nov; 60(9):1251-65. PubMed ID: 11008119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant human immunodeficiency virus.
    Mao C; Sudbeck EA; Venkatachalam TK; Uckun FM
    Antivir Chem Chemother; 1999 Sep; 10(5):233-40. PubMed ID: 10574178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    D'Cruz OJ; Uckun FM
    J Enzyme Inhib Med Chem; 2006 Aug; 21(4):329-50. PubMed ID: 17059165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission.
    D'Cruz OJ; Uckun FM
    Curr HIV Res; 2006 Jul; 4(3):329-45. PubMed ID: 16842085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico structure-based design of a potent, mutation resilient, small peptide inhibitor of HIV-1 reverse transcriptase.
    Rao GS; Bhatnagar S
    J Biomol Struct Dyn; 2003 Oct; 21(2):171-8. PubMed ID: 12956603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural requirements for potent anti-human immunodeficiency virus (HIV) and sperm-immobilizing activities of cyclohexenyl thiourea and urea non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    D'Cruz OJ; Venkatachalam TK; Mao C; Qazi S; Uckun FM
    Biol Reprod; 2002 Dec; 67(6):1959-74. PubMed ID: 12444075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.
    Hsiou Y; Das K; Ding J; Clark AD; Kleim JP; Rösner M; Winkler I; Riess G; Hughes SH; Arnold E
    J Mol Biol; 1998 Nov; 284(2):313-23. PubMed ID: 9813120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.
    Hsiou Y; Ding J; Das K; Clark AD; Boyer PL; Lewi P; Janssen PA; Kleim JP; Rösner M; Hughes SH; Arnold E
    J Mol Biol; 2001 Jun; 309(2):437-45. PubMed ID: 11371163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
    Uckun FM; Mao C; Pendergrass S; Maher D; Zhu D; Tuel-Ahlgren L; Venkatachalam TK
    Bioorg Med Chem Lett; 1999 Sep; 9(18):2721-6. PubMed ID: 10509923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reserve transcriptase.
    Vig R; Mao C; Venkatachalam TK; Tuel-Ahlgren L; Sudbeck EA; Uckun FM
    Bioorg Med Chem; 1998 Oct; 6(10):1789-97. PubMed ID: 9839009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.
    Mao C; Sudbeck EA; Venkatachalam TK; Uckun FM
    Bioorg Med Chem Lett; 1999 Jun; 9(11):1593-8. PubMed ID: 10386942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design of N-[2-(1-piperidinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Mao C; Vig R; Venkatachalam TK; Sudbeck EA; Uckun FM
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2213-8. PubMed ID: 9873515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
    Zhou Z; Madrid M; Evanseck JD; Madura JD
    J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants.
    Frey KM; Puleo DE; Spasov KA; Bollini M; Jorgensen WL; Anderson KS
    J Med Chem; 2015 Mar; 58(6):2737-45. PubMed ID: 25700160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
    Xu Z; Guo J; Yang Y; Zhang M; Ba M; Li Z; Cao Y; He R; Yu M; Zhou H; Li X; Huang X; Guo Y; Guo C
    Eur J Med Chem; 2016 Nov; 123():309-316. PubMed ID: 27484516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent dual anti-HIV and spermicidal activities of novel oxovanadium(V) complexes with thiourea non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    D'Cruz OJ; Dong Y; Uckun FM
    Biochem Biophys Res Commun; 2003 Mar; 302(2):253-64. PubMed ID: 12604339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles.
    Roth T; Morningstar ML; Boyer PL; Hughes SH; Buckheit RW; Michejda CJ
    J Med Chem; 1997 Dec; 40(26):4199-207. PubMed ID: 9435891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
    Xu Z; Ba M; Zhou H; Cao Y; Tang C; Yang Y; He R; Liang Y; Zhang X; Li Z; Zhu L; Guo Y; Guo C
    Eur J Med Chem; 2014 Oct; 85():27-42. PubMed ID: 25072874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of stereo and regiochemistry towards wild and multidrug resistant HIV-1 virus: viral potency of chiral PETT derivatives.
    Venkatachalam TK; Mao C; Uckun FM
    Biochem Pharmacol; 2004 May; 67(10):1933-46. PubMed ID: 15130770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
    Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.